Cargando…

The impact of insurance status on progression-free survival (PFS) and overall survival (OS) in patients with metastatic renal cell carcinoma (mRCC)

BACKGROUND: In addition to the previously studied socioeconomic factors associated with health disparities, insurance status can serve as a prognostic factor associated with overall survival in RCC patients (Zhang et al., Future Oncol 2019). Moreover, within this population, having access to health...

Descripción completa

Detalles Bibliográficos
Autores principales:	Castro, Daniela, Tripathi, Nishita, Sayegh, Nicolas, Gebrael, Georges, Li, Xiaochen, Meza, Luis, Zengin, Zeynep, Chehrazi-Raffle, Alex, Govindarajan, Ameish, Dizman, Nazli, Ebrahimi, Hedyeh, Chawla, Neal, Mercier, Benjamin, Hsu BS, JoAnn, Shi, Jessica, Philip, Errol, Bergerot, Cristiane, Barragan-Carrillo, Regina, Pal, Sumanta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Rapid Abstract Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10445577/ http://dx.doi.org/10.1093/oncolo/oyad216.008

Ejemplares similares

Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden
por: Maia, Manuel Caitano, et al.
Publicado: (2017)

CT-based radiomics model for the prediction of genomic alterations in renal cell carcinoma (RCC)
por: Ebrahimi, Hedyeh, et al.
Publicado: (2023)

Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles
por: Govindarajan, Ameish, et al.
Publicado: (2023)

Metastasis in renal cell carcinoma: Biology and implications for therapy
por: Gong, Jun, et al.
Publicado: (2016)

Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?
por: Shah, Amishi Y., et al.
Publicado: (2015)

Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2021)

Impact of Time to Metastasis (Synchronous vs. Metachronous) on Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with First Line Immune-Checkpoint Inhibitors (ICI)-based Combinations
por: Meza, Luis, et al.
Publicado: (2023)

Long-term survival in unfavourable-risk mRCC patients after intratumoral administration of a cell-based allogeneic vaccine
por: Karlsson-Parra, Alex, et al.
Publicado: (2015)

Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis
por: Meza, Luis, et al.
Publicado: (2023)

SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
por: Nuijten, M, et al.
Publicado: (2010)

DNA Methylation Biomarkers Predict Progression-Free and Overall Survival of Metastatic Renal Cell Cancer (mRCC) Treated with Antiangiogenic Therapies
por: Peters, Inga, et al.
Publicado: (2014)

28-Year Survival following Several Metastasectomies, Going through 8th Line Systemic Therapy in a Case of mRCC
por: Magdy, A., et al.
Publicado: (2015)

Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
por: Wang, Y, et al.
Publicado: (2014)

Unlikely association of nephrectomy post-mRCC with anti-VEGF-induced renal TMA
por: Izzedine, Hassane, et al.
Publicado: (2011)

Systemic therapy in metastatic renal cell carcinoma (mRCC): an evidence-based recommendation of the German interdisciplinary RCC guidelines group
por: Grünwald, V., et al.
Publicado: (2022)

Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapy
por: Bergerot, Cristiane Decat, et al.
Publicado: (2019)

Reply: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
por: Thompson Coon, J S, et al.
Publicado: (2010)

Improving survival in metastatic renal cell carcinoma (mRCC) patients: do elderly patients benefit from expanded targeted therapeutic options?
por: Eggers, Hendrik, et al.
Publicado: (2022)

First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC
por: Ko, J J, et al.
Publicado: (2014)

Letter to the Editor: SUN vs BEVþIFN in first-line mRCC therapy: no evidence for a statistically significant difference in progression-free survival
por: Nuijten, M, et al.
Publicado: (2010)

Sunitinib Enables a Clinical and Pathological Complete Remission of Metastatic Renal Cell Carcinoma (mRCC)
por: Peng, Bo, et al.
Publicado: (2017)

Assessment of prognosis by established prognosis scores and physicians’ judgement in mRCC patients: an analysis of the STAR-TOR registry
por: Boegemann, Martin, et al.
Publicado: (2021)

Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California
por: Salgia, Nicholas J., et al.
Publicado: (2021)

Vorolanib and everolimus: Lenvatinib and everolimus part deux, or something new?
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2020)

An Update on the Treatment of Papillary Renal Cell Carcinoma
por: Chawla, Neal S., et al.
Publicado: (2023)

Axitinib for the treatment of patients with advanced metastatic renal cell carcinoma (mRCC) after failure of prior systemic treatment
por: Grünwald, Viktor, et al.
Publicado: (2012)

Host immune signatures as predictors of response to immunotherapy-based regimens in patients with metastatic renal cell carcinoma (mRCC)
por: Saad, Eddy, et al.
Publicado: (2023)

Regulatory T-Cells and Associated Pathways in Metastatic Renal Cell Carcinoma (mRCC) Patients Undergoing DC-Vaccination and Cytokine-Therapy
por: Schwarzer, Adrian, et al.
Publicado: (2012)

Imaging Response of Antiangiogenic and Immune-Oncology Drugs in Metastatic Renal Cell Carcinoma (mRCC): Current Status and Future Challenges
por: Fournier, Laure, et al.
Publicado: (2017)

How to Treat Renal Cell Carcinoma: The Current Treatment Landscape and Cardiovascular Toxicities
por: Castro, Daniela V., et al.
Publicado: (2022)

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
por: Dizman, Nazli, et al.
Publicado: (2022)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020)

Randomized trial assessing impact of probiotic supplementation on gut microbiome and clinical outcome from targeted therapy in metastatic renal cell carcinoma
por: Dizman, Nazli, et al.
Publicado: (2020)

Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma
por: Chehrazi-Raffle, Alexander, et al.
Publicado: (2023)

Clinical-Based vs. Model-Based Adaptive Dosing Strategy: Retrospective Comparison in Real-World mRCC Patients Treated with Sunitinib
por: Ferrer, Florent, et al.
Publicado: (2021)

Real-World Treatment with Nivolumab or Cabozantinib for Metastatic Renal Cell Carcinoma (mRCC) in the Veneto Region of Italy: Results of AMOUR Study
por: Maruzzo, Marco, et al.
Publicado: (2022)

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM(SM) registry
por: Fishman, M., et al.
Publicado: (2019)

Correlation of genomic alterations assessed by next-generation sequencing (NGS) of tumor tissue DNA and circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC): potential clinical implications
por: Hahn, Andrew W., et al.
Publicado: (2017)

Front-Line Therapy for Metastatic Renal Cell Carcinoma: A Perspective on the Current Algorithm and Future Directions
por: Govindarajan, Ameish, et al.
Publicado: (2022)

Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)
por: Seidel, C, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_manfu20qsf2kvepjkt62d5v392